PROLENSA

This brand name is authorized in United States. It is also authorized in Canada.

Active ingredients

The drug PROLENSA contains one active pharmaceutical ingredient (API):

1	Bromfenac UNII 8ECV571Y37 - BROMFENAC SODIUM
	Bromfenac is a topical, nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. It is indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery. The mechanism of its action is thought to be due to its ability to block prostaglandin synthesis by inhibiting cyclooxygenase 1 and 2. The most commonly reported adverse reactions in 3 to 8% of patients were anterior chamber inflammation, foreign body sensation, eye pain, photophobia and vision blurred.
	Read more about Bromfenac

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
PROLENSA Ophthalmic solution	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
S01BC11		S Sensory organs → S01 Ophthalmologicals → S01B Antiinflammatory agents → S01BC Antiinflammatory agents, non-steroids
Discover more medicines within S01BC11

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02439123
US	FDA, National Drug Code	24208-602